⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FBLG News
FibroBiologics, Inc. Common Stock
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
globenewswire.com
FBLG
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
globenewswire.com
FBLG
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
globenewswire.com
FBLG
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
globenewswire.com
FBLG
Form 8-K
sec.gov
FBLG
FibroBiologics CEO Issues Letter to Shareholders
globenewswire.com
FBLG
Form 8-K
sec.gov
FBLG
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
globenewswire.com
FBLG
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
globenewswire.com
FBLG
Form 8-K
sec.gov
FBLG